Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum

Acta Oncologica

Volumn 41, Issue 5, 2002, Pages 418-424

  Rosenberg, Per ^a   Andersson, Håkan ^a   Boman, Karin ^a   Ridderheim, Mona ^a   Sorbe, Bengt ^a   Puistola, Ulla ^a   Parö, Gunnar ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DOSAGE; PLATINUM; TOXICITY; TUMORS;

ADVANCED OVARIAN CANCER; INTRAVENOUS STEROID PREMEDICATION;

ONCOLOGY;

CIMETIDINE; CISPLATIN; CLEMASTINE; CORTICOSTEROID; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; PLATINUM; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; SKIN ALLERGY; THROMBOCYTOPENIA; TREATMENT OUTCOME; URTICARIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CIMETIDINE; CLEMASTINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LIFE TABLES; MIDDLE AGED; MUSCULAR DISEASES; NERVOUS SYSTEM DISEASES; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL; PREMEDICATION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036407202     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418602320404998     Document Type: Article

References (24)

1. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
2. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in woman with advanced epithelial ovarian cancer. J Natl Cancer Inst. 2000; 92: 699-708.
3. Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-cased chemotherapy: A gynecologic oncology group study. J Clin Oncol 1994; 12: 1748-53.
4. Seewaldt V, Greer BE, Cain JM, et al. Paclitaxel (Taxol) treatment for refractory ovarian cancer: Phase II clinical trial. Am J Obstet Gynecol 1994; 170: 1666-71.
5. Gore ME, Levy V, Rustin G. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: The UK and Eire experience. Br J Cancer 1995; 72: 1016-9.
6. Trimble EL, Adams JD, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to the National Cancer Institute treatment referral center 9103. J Clin Oncol 1993; 11: 2405-10.
7. Einzig AI, Wiernik PH, Sasloff J, et al. Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10: 1748-56.
8. Philips KA, Friedlander M, Olver I. Australasian multicenter phase II study of paclitaxel (Taxol) in relapsed ovarian cancer. Aust NJZ Med 1995; 25: 337-43.
9. duBois A, Lück HJ, Buser K, et al. Extended Phase II study of pPaclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum. Eur J Cancer 1997; 33: 379-84.
10. Tropé C, Högberg T, Kaern J, et al. Long term results from a phase-II study of single agent paclitaxel (Taxol®) in previously platinum treated patients with advanced ovarian cancer. The NORDIC experience. Ann Oncol 1998; 9: 1301-7.
11. Andersson H, Horvath G, Mellqvist L. Taxol given weekly in advanced previously treated ovarian carcinomas - A pilot study. Int J Gynecol Cancer 1997; 7: 262-6.
12. Fenelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacological study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15: 187-92.
13. Klaasen U, Wilke H, Strumberg D, et al. Phase I study with a weekly 1-h infusion of paclitaxel in heavily pretreated patients with metastatic and ovarian cancer. Eur J Cancer 1996; 32A: 547-9.
14. Choy H, Safran H, Akerley W, et al. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced inoperable non-small cell lung cancer. Proc Am Soc Clin Oncol 1998; 17: 1794 (Abstr).
15. Belani C, Aisner J, Day R, et al. Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy for locally advanced non-small cell lung cancer: Three year follow-up. Proc Am Soc Clin Oncol 1997; 16: 1608 (Abstr).
16. WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication N.48, 1979.
17. Eisenhauer EA, ten Bokkel Huinik WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66.
18. Lopes NM, Adams EF, Pitts TW, Bhuyan BK. Cell kill kinetics and cell cycles effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993; 32: 235-42.
19. Seidman AD, Hochhauser D, Gollub M, et al. Ninety-six hour paclitaxel infusion after progression during short taxane exposure: A phase 11 pharmacokinetic and pharmacodynamic study in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1877-84.
20. Chang AY, Boros L, Garrow R, et al. Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease. Semin Oncol 1995; 22 (Suppl 6): 124-7.
21. Abu-Rustum NR, Aghajanian C, Barakat RR, et al. Salvage weekly paclitaxel in recurrent ovarian cancer. Semin Oncology 1997; 24 (Suppl 15): 62-7.
22. Markman M, Kennedy A, Webster K, et al. Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions. J Clin Oncol 1997; 15: 3517.
23. Bookman MA, Kloth DD, Kover PE, et al. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 1997; 8: 611-4.
24. Högberg T, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 2001; 40: 340-60.